Institut de Cancérologie de l'Ouest… · Institution

The Institut de Cancérologie de l'Ouest was created by merging the Centre Paul Papin in Angers and the Centre René Gauducheau in Saint-Herblain near Nantes, and is one of the 18 Centres de Lutte Contre le Cancer of the Unicancer network. It delivers surgery, radiotherapy, medical oncology and nuclear medicine across the Pays de la Loire, hosts an early-phase trials unit, and works with the universities of Angers and Nantes and Inserm on radiopharmaceuticals, alpha-emitter therapy and immuno-oncology, drawing on the Nantes nuclear medicine and cyclotron infrastructure. The ICO is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.

Location

Angers, FR

Type

cancer center

Website

www.institut-cancerologie-ouest.com

Newsweek 2026 oncology rank

Not in top 300 listing used

OnCo score

#464 · 8 points (0 Newsweek + 0 NCI + 8 from 4 linked objects) · ranking

Research output

From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.

Matched to Institut de Cancérologie de l'Ouest, including child institutions. 423 works · 4,767 citations · 68% open access · 16% clinical trials · 0% reviews.

Oncology works per year

772022

982023

902024

862025

722026

Most works

Most cited

Work	Journal	Year	Citations
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 10.1016/s0140-6736(22)02420-5 · open access	The Lancet	2022	681
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study 10.1016/s1470-2045(22)00226-1 · open access	The Lancet Oncology	2022	454
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022 10.1016/j.ejca.2022.03.008 · open access	European Journal of Cancer	2022	331
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial 10.1016/j.annonc.2024.06.019 · open access	Annals of Oncology	2024	220
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022 10.1016/j.ejca.2022.03.043 · open access	European Journal of Cancer	2022	184
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial 10.1016/j.annonc.2022.06.011 · open access	Annals of Oncology	2022	159
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors 10.1001/jamanetworkopen.2023.41165 · open access	JAMA Network Open	2023	133
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. conference abstract · 10.1200/jco.2023.41.17_suppl.lba3504	Journal of Clinical Oncology	2023	110
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial 10.1038/s41591-023-02572-5 · open access	Nature Medicine	2023	99
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma 10.1016/j.annonc.2024.08.2239 · open access	Annals of Oncology	2024	84
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study 10.1016/s0140-6736(24)00814-6 · open access	The Lancet	2024	84
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial 10.1136/ijgc-2023-004995 · open access	International Journal of Gynecological Cancer	2023	64
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial 10.1200/po.22.00258 · open access	JCO Precision Oncology	2023	58
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer 10.1038/s41416-024-02766-9 · open access	British Journal of Cancer	2024	55
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study. conference abstract · 10.1200/jco.2023.41.4_suppl.4 · open access	Journal of Clinical Oncology	2023	48

Programmes

3top

Radiopharmaceuticals and alpha therapy
Early-phase trials
Radiotherapy

People

1top

Mario Campone

Directeur Général (Director General), Institut de Cancérologie de l'Ouest

Medical oncologyBreast cancerCancer centre management

Medical oncologist who is Director General of the Institut de Cancérologie de l'Ouest, the regional cancer centre for western France with sites in Angers and Nantes.

Connected

5top

Institution
Institut du Cancer de Montpellier (ICM)
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre François Baclesse
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Jean Perrin
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Henri Becquerel
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Centre Eugène Marquis
Shares UNICANCER, Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre, unicancer.
Institution
Hospital Universitario Fundación Jiménez Díaz
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
University Medical Center Groningen Comprehensive Cancer Center
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.
Institution
ASST Spedali Civili di Brescia
Shares Organisation of European Cancer Institutes and the tags oeci-accredited, oeci-comprehensive-cancer-centre.

Institut de Cancérologie de l'Ouest (ICO)

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Institut de Cancérologie de l'Ouest (ICO)

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Institut de Cancérologie de l'Ouest (ICO)

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people

Institut de Cancérologie de l'Ouest (ICO)

Overview

Research output

Programmes

People

Connected

Similar pages

technologies

companies

institutions

people